Literature DB >> 8470631

Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients.

F Salerno1, G Borroni, P Moser, S Badalamenti, L Cassarà, A Maggi, M Fusini, B Cesana.   

Abstract

Ascites is a complication of chronic liver disease that is associated with decreased survival. The purpose of the present study was to identify some prognostic factors easily obtainable by the clinician in a large group of cirrhotic patients with ascites, possibly useful for first screening of outpatients as candidates for liver transplantation. We studied 134 ambulatory patients with cirrhosis who came to our outpatient clinic between July 1983 and March 1989 because of an episode of ascites. These patients were then followed up for an average period of 31 +/- 23 months and survival was determined. Thirty-one variables determined at the time of inclusion were analyzed with a Cox proportional hazards model to identify predictors of mortality. Cumulative mortality as of June 30, 1991, was 59%. Factors independently correlated with death were: refractory ascites (relative risk, 4.78), low albumin levels (3.77), high Child-Pugh score (3.31), encephalopathy (2.71), high bilirubin levels (2.03), high gamma-glutamyl-transferase levels (1.87), and old age (1.57). The results show that 1) the occurrence of refractory ascites has a prognostic value superior to those of other variables, and 2) simple clinical and biochemical parameters, most of them components of the Child-Pugh score, are useful for a first screening of ascitic cirrhotic patients as candidates for liver transplantation.

Entities:  

Mesh:

Year:  1993        PMID: 8470631

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  29 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis.

Authors:  Maximilian Jara; Tomasz Dziodzio; Maciej Malinowski; Katja Lüttgert; Radoslav Nikolov; Paul Viktor Ritschl; Robert Öllinger; Johann Pratschke; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2018-11-07       Impact factor: 3.199

3.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

4.  Hepatic encephalopathy therapy: An overview.

Authors:  Oliviero Riggio; Lorenzo Ridola; Chiara Pasquale
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-04-06

5.  Post-operative Ascites After Hepatectomy-Not More Than What Meets the Eyes.

Authors:  Sri Siddhartha Nekkanti; Sridhar Sundaram; Shraddha Patkar; Mahesh Goel
Journal:  J Gastrointest Surg       Date:  2021-06-15       Impact factor: 3.452

6.  High relative fat-free mass is important for maintaining serum albumin levels in patients with compensated liver cirrhosis.

Authors:  Kazuhiro Kotoh; Makoto Nakamuta; Marie Fukushima; Chitose Matsuzaki; Munechika Enjoji; Hironori Sakai; Hajime Nawata
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

7.  Trans-jugular intrahepatic porto-systemic shunt placement for refractory ascites: a 'real-world' UK health economic evaluation.

Authors:  Matthew J Parker; Neil Guha; Brian Stedman; Nigel Hacking; Mark Wright
Journal:  Frontline Gastroenterol       Date:  2012-03-22

8.  Risk Factors for Postoperative Ascites in Patients Undergoing Liver Resection for Hepatocellular Carcinoma.

Authors:  Takahiro Yoshikawa; Takeo Nomi; Daisuke Hokuto; Satoshi Yasuda; Chihiro Kawaguchi; Takatsugu Yamada; Hiromichi Kanehiro; Yoshiyuki Nakajima
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

9.  Adverse outcomes in patients with postoperative ascites after liver resection for hepatocellular carcinoma.

Authors:  Kun-Ming Chan; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Ming-Chin Yu; Wei-Chen Lee; Miin-Fu Chen
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

10.  Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.

Authors:  K Stein; W Rosenberg; J Wong
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.